ALPHA TAU MEDICAL LTD (DRTS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:DRTS • IL0011839383

6.94 USD
-0.3 (-4.14%)
At close: Jan 30, 2026
6.81 USD
-0.13 (-1.87%)
After Hours: 1/30/2026, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DRTS. DRTS was compared to 184 industry peers in the Health Care Equipment & Supplies industry. The financial health of DRTS is average, but there are quite some concerns on its profitability. DRTS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • DRTS had negative earnings in the past year.
  • In the past year DRTS has reported a negative cash flow from operations.
  • DRTS had negative earnings in each of the past 5 years.
  • DRTS had a negative operating cash flow in each of the past 5 years.
DRTS Yearly Net Income VS EBIT VS OCF VS FCFDRTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • DRTS's Return On Assets of -31.73% is in line compared to the rest of the industry. DRTS outperforms 41.30% of its industry peers.
  • The Return On Equity of DRTS (-40.64%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -31.73%
ROE -40.64%
ROIC N/A
ROA(3y)-30.7%
ROA(5y)-34.69%
ROE(3y)-39.04%
ROE(5y)-55.73%
ROIC(3y)N/A
ROIC(5y)N/A
DRTS Yearly ROA, ROE, ROICDRTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • DRTS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRTS Yearly Profit, Operating, Gross MarginsDRTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

6

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, DRTS has more shares outstanding
  • The number of shares outstanding for DRTS has been increased compared to 5 years ago.
  • DRTS has a worse debt/assets ratio than last year.
DRTS Yearly Shares OutstandingDRTS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
DRTS Yearly Total Debt VS Total AssetsDRTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 12.85 indicates that DRTS is not in any danger for bankruptcy at the moment.
  • DRTS has a better Altman-Z score (12.85) than 91.85% of its industry peers.
  • A Debt/Equity ratio of 0.07 indicates that DRTS is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.07, DRTS is doing good in the industry, outperforming 66.30% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 12.85
ROIC/WACCN/A
WACCN/A
DRTS Yearly LT Debt VS Equity VS FCFDRTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 10.52 indicates that DRTS has no problem at all paying its short term obligations.
  • DRTS's Current ratio of 10.52 is amongst the best of the industry. DRTS outperforms 92.93% of its industry peers.
  • A Quick Ratio of 10.52 indicates that DRTS has no problem at all paying its short term obligations.
  • DRTS's Quick ratio of 10.52 is amongst the best of the industry. DRTS outperforms 94.57% of its industry peers.
Industry RankSector Rank
Current Ratio 10.52
Quick Ratio 10.52
DRTS Yearly Current Assets VS Current LiabilitesDRTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1

3. Growth

3.1 Past

  • DRTS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.93%.
EPS 1Y (TTM)-20.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, DRTS will show a very strong growth in Earnings Per Share. The EPS will grow by 27.08% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-16.22%
EPS Next 2Y-4.36%
EPS Next 3Y5.27%
EPS Next 5Y27.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DRTS Yearly Revenue VS EstimatesDRTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
DRTS Yearly EPS VS EstimatesDRTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1

0

4. Valuation

4.1 Price/Earnings Ratio

  • DRTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRTS Price Earnings VS Forward Price EarningsDRTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRTS Per share dataDRTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.36%
EPS Next 3Y5.27%

0

5. Dividend

5.1 Amount

  • No dividends for DRTS!.
Industry RankSector Rank
Dividend Yield 0%

ALPHA TAU MEDICAL LTD / DRTS FAQ

What is the fundamental rating for DRTS stock?

ChartMill assigns a fundamental rating of 2 / 10 to DRTS.


What is the valuation status for DRTS stock?

ChartMill assigns a valuation rating of 0 / 10 to ALPHA TAU MEDICAL LTD (DRTS). This can be considered as Overvalued.


What is the profitability of DRTS stock?

ALPHA TAU MEDICAL LTD (DRTS) has a profitability rating of 1 / 10.


Can you provide the financial health for DRTS stock?

The financial health rating of ALPHA TAU MEDICAL LTD (DRTS) is 6 / 10.


Can you provide the expected EPS growth for DRTS stock?

The Earnings per Share (EPS) of ALPHA TAU MEDICAL LTD (DRTS) is expected to decline by -16.22% in the next year.